The UK and US have concluded a significant bilateral deal that will guarantee no levies on British drug exports being sold in the US market.
The Terms of the Accord
As part of the deal, the UK has committed to increase spending on drugs through the public health system. This pledge ensures that duties on these vital goods will be held at nothing for a duration of 36 months.
This development follows previous statements to dramatically increase tariffs on branded drug imports, with potential rates floated up to double the cost.
"This deal between the Britain reinforces the global environment for new treatments and introduces much-needed fairness to U.S.–U.K. medicine commerce," an announcement said.
Economic Importance
Pharmaceuticals constitute one of the Britain's largest goods shipped to the United States, which is clearly the primary buyer for large UK drugmakers.
Export figures reveal that in the year prior to September, the UK exported drugs worth £11.1bn to the US. This value represented nearly one-fifth of British export trade in that period.
"This agreement secures work, stimulates capital expenditure and paves the way for the UK to establish itself as a international leader for life sciences," a minister remarked.
Detailed British Pledges
The deal includes several specific changes from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it deems new medicines to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to increase total health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The percentage manufacturers must refund to the NHS to control costs will be capped at fifteen percent. Last year, rebates exceeded 20%.
Industry Background
The pact comes amid a protracted row between the pharmaceutical industry and the UK government over drug pricing and NHS adoption.
These tensions were exacerbated by arguments that US patients were charged a premium for the equivalent treatments than patients in the UK and Europe.
In recent months, several major pharmaceutical investments in the UK have been paused or scrapped, while major investments have been pledged toward American operations.
One official publicly accepted that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had decreased as a share of its overall budget over the past decade.
